# A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

> **NCT06492616** · PHASE3 · RECRUITING · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 4220 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Elacestrant
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT06492616
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-27
- **Primary completion:** 2029-08
- **Final completion:** 2032-10
- **Target enrollment:** 4220 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492616, "A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06492616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*